Extended Data Fig. 4: Analysis of neutralization breadth of MARV monoclonal antibodies.
From: Potent neutralization of Marburg virus by a vaccine-elicited antibody
a–m, Neutralization dose-response curves for MARV16, MR78, MR191, and EBOV515 against VSV pseudotyped with the MARV/Musoke GP (a), MARV/Angola GP (b), MARV/Ci67 GP (c), MARV/Equatorial Guinea-2023 GP (d), MARV/Kakbat-SL-2017 GP (e), MARV/Kasbat-SL-2018 GP (f), MARV/Ozolin GP (g), MARV/Ghana-2022 GP (h), RAVV GP (i), DEHV GP (j), MLAV GP (k), EBOV GP (l), or SUDV GP (m). Each of the two to six biological replicates used distinct batches of pseudoviruses and antibodies and data are shown as the mean ± standard error of technical triplicates.
